A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD
ALN-APP-001
Phase 1 other active
Quick answer
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD for Early-onset Alzheimer's disease (EOAD) is a Phase 1 program (other) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alnylam Netherlands B.V.
- Indication
- Early-onset Alzheimer's disease (EOAD)
- Phase
- Phase 1
- Modality
- other
- Status
- active